Cancer Clinical Research Unit

Key Inclusion Criteria: - At least 18 years of age, or country defined local legal age - Demonstrated adequate organ function at screening - Life expectancy >12 weeks as determined by the Investigator - Female and male participants of childbearing potential who are sexually active must agree to use highly effective methods of contraception - Participants must have histologically confirmed locally advanced, recurrent, or metastatic solid tumor malignancies that cannot be treated with curative intent (surgery or radiotherapy), with the exception of the neoadjuvant cohorts - Part 1 and Part 2: Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2 - Part 3 and Part 4: Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 - Participants who have undergone treatment with anti-PD-1, anti-PD-L1, or anti-cytotoxic T-lymphocyte-associated protein (CTLA-4) antibody must have a washout of at least 4 weeks from the last dose and evidence of disease progression per investigator assessment before Cycle 1 Day 1 (C1D1) with the exception of the neoadjuvant cohorts - Participants who have previously received an immunotherapy prior to C1D1 must have any immune-related toxicities resolved to ≤Grade 1 or baseline (prior to the immunotherapy) to be eligible, with the exception of participants on well controlled physiologic endocrine replacement - Part 3: Neoadjuvant cohorts: participants must have completely resectable disease Key Exclusion Criteria: - Symptomatic central nervous system metastases and/or carcinomatous meningitis - Active autoimmune diseases, regardless of need for immunosuppressive treatment, with the exception of participants well controlled on physiologic endocrine replacement - Any uncontrolled bacterial, fungal, viral, or other infection - Significant cardiac disease - A marked clinically significant baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >480 ms) [CTCAE Grade 1]) using Fridericia's QT correction formula - Positive for human immunodeficiency virus (HIV) or has known active hepatitis B or C infection - Known hypersensitivity to any study treatment(s) used in the specific study part/cohort - Participants who have been previously treated with IL-2 or IL-2 variants (all participants) - Systemic immunosuppressive treatment with the exception for patients on corticosteroid taper (for example, for chronic obstructive pulmonary disease exacerbation). - Vaccination with live, attenuated vaccines within 4 weeks of C1D1 - Treatment with any other anti-cancer systemic treatment (approved or investigational) or radiation therapy within 4 weeks of C1D1 - Part 3: Other active malignancies within the last 2 years - Women who are breastfeeding or have a positive serum pregnancy test during screening